Semiglutide

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with a prolonged half-life of approximately 7 days^[1], approved for chronic weight management and glycemic control. The extended half-life enables once-weekly subcutaneous dosing, which is the standard clinical approach^[1]. This educational protocol presents a gradual weekly titration from 0.25 mg up to a maintenance dose of 2.4 mg over 16+ weeks, using a practical dilution for precise insulin-syringe measurements.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.
• Weekly dose range: 250–2400 mcg (0.25–2.4 mg) once weekly (gradual escalation protocol).